865-299-6250 info@edpbiotech.com
 Comment  Print

Chairman Tom Boyd, CEO Eric Mayer

KNOXVILLE’s EDP Biotech, which was chartered to commercialize assays for early detection of disease and is now focused on its blood-based ColoPlex™ test for colorectal cancer, is pursuing a $5MM raise to propel its work alongside strategic partners.

The Series A preferred capital raise was confirmed today by CEO Eric Mayer, the 35-year-old who leads the company, the board of which is chaired by Knoxville serial entrepreneur Tom Boyd.

The company has raised $17.5MM previously, mainly through friends, family and high net worth individuals. Some of its raises are represented in SEC Form D filings here.

Read the full article at VNC here!